Cerebral Infarction, Thrombolysis
Conditions
Brief summary
This study evaluates whether early administration of low-dose aspirin (100mg) at 2 hours post-intravenous thrombolysis, compared to the standard timing of 24 hours, improves functional outcomes in patients with acute ischemic stroke. Intravenous thrombolysis is effective for very early treatment of acute ischemic stroke. However, current guidelines recommend starting antiplatelet therapy 24 hours after thrombolysis to avoid symptomatic intracranial hemorrhage (SICH), a recommendation not based on prospective clinical studies. Early re-occlusion of recanalized arteries due to platelet aggregation occurs in 14-34% of cases and is associated with poor prognosis. The average incidence of SICH is 2.4%, with fatal SICH occurring in only 0.28%. Thus, the impact of re-occlusion on poor prognosis may outweigh the risk of SICH. In this prospective, randomized, open-label trial with blinded endpoint evaluation, participants are assigned to receive aspirin 100mg either at 2 hours (early group) or at 24 hours (standard group) after thrombolysis. The primary outcome is the proportion of patients with a favorable functional outcome, defined as a modified Rankin Scale (mRS) score of 0-2 at 3 months. Safety outcomes include the incidence of SICH and all-cause mortality at 3 months. This study will provide clinical evidence regarding the optimal timing for initiating antiplatelet therapy after thrombolysis in acute ischemic stroke.
Interventions
DRUGAspirin (Early, 2h)
Aspirin 100mg orally, administered once daily. The first dose is given at 2 hours after rt-PA thrombolysis, conditional on a follow-up CT scan at 2 hours excluding intracranial hemorrhage. Treatment continues for 3 months.
DRUGAspirin (Standard, 24h)
Aspirin 100mg orally, administered once daily. The first dose is given at 24 hours after rt-PA thrombolysis, conditional on a follow-up CT scan at 24 hours confirming no intracranial hemorrhage. Treatment continues for 3 months.
Sponsors
Beijing Chao Yang Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Age range: 18-65 years old 2. Receive rt PA thrombolytic therapy within 3 hours (including 3 hours) of onset 3. Signs of brain dysfunction lasting for more than 1 hour 4. CT imaging excludes cerebral hemorrhage, and there are no imaging changes corresponding to the patient's physical signs
Exclusion criteria
1. Age\>65 years old 2. Onset time\>3 hours 3. Accompanied by consciousness disorders, or NIHSS ≥ 20 points 4. CT shows' high-density shadow of middle cerebral artery ' 5. Accompanied by atrial fibrillation or clearly identified as cardioembolic embolism 6. Severe swallowing difficulties, unable to take medication orally 7. Oral anticoagulant medication is currently being taken 8. Accompanied by severe infection or evidence of severe infection 9. Refusal to sign the informed consent form for this study 10.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of Patients with Favorable Functional Outcome at 3 Months | 3 months | Favorable functional outcome is defined as a score of 0 to 2 on the modified Rankin Scale (mRS). The mRS score will be assessed by a blinded endpoint assessor at 3 months post-stroke via a structured telephone interview or during a clinic visit. |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of symptomatic intracranial hemorrhage | 24 hour |
| Patient mortality rate at 3 months | 3 months |
Countries
China
Contacts
CONTACTMing Lu, MD
Outcome results
None listed